Drugs / Psilocybin
Psilocybin
Trials 243 · started per year
today
1
1
1
2
1
2
4
3
4
4
6
5
20
20
34
41
45
46
2
1
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 019 trials | ||||||
| Phase 0 | NCT06102434 | Feb → May 2029 | substance-related disorder | University of California, Los Angeles | Suspended | No outcome recorded |
| Phase 0 | NCT07565493 | Aug 2026 → Jun 2028 expected | — | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 0 | NCT06760533 | Aug → Dec 2026 expected | irritable bowel syndrome | NYU Langone Health | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07118332 | Jul 2026 → Oct 2027 expected | — | Yale University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06724289 | Mar 2026 → Aug 2027 expected | — | University of Virginia | Recruiting | No outcome recorded |
| Phase 0 | NCT06798636 | Oct 2025 → Aug 2026 overdue | — | Imperial College London | Recruiting | No outcome recorded |
| Phase 0 | NCT06464367 | May 2025 → Dec 2027 expected | migraine disorder | Yale University | Recruiting | No outcome recorded |
| Phase 0 | NCT06656702 | Apr 2025 → Jan 2027 expected | amyotrophic lateral sclerosis | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 0 | NCT06899594 | Apr 2025 → Mar 2027 expected | methamphetamine dependence | Kevin Murnane | Recruiting | No outcome recorded |
| Phase 0 | NCT05068791 | Nov 2023 → Dec 2026 expected | fibromyalgia | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 0 | NCT05958758 | Sep 2023 → Apr 2025 | — | The Roots to Thrive Society for Psychedelic Therapy | Unknown | No outcome recorded |
| Phase 0 | NCT05227742 | Aug 2023 → Mar 2026 | — | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 0 | NCT05252598 | Jan → Aug 2023 | anxiety, mood disorder, poisoning, sleep disorder | Optimi Health Corporation | Withdrawn | No outcome recorded |
| Phase 0 | NCT05546658 | Nov 2022 → Sep 2026 expected | obsessive-compulsive disorder | Johns Hopkins University | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04522804 | Oct 2021 → Jun 2022 | cancer | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT04501653 | Jun 2021 → Mar 2023 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT04123314 | Mar 2021 → Sep 2026 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia, depressive disorder | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 0 | NCT03604744 | Mar 2019 → Apr 2021 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 0 | NCT00957359 | Feb 2009 → Sep 2018 | cancer | NYU Langone Health | Completed | No outcome recorded |
| Phase 171 trials | ||||||
| Phase 1 | NCT07360301 | Sep 2026 → Feb 2028 expected | — | University of Wisconsin, Madison | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07406828 | Jul 2026 → Aug 2027 expected | — | Trent Emerick | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07607938 | Jul 2026 → Aug 2030 expected | atypical depressive disorder | NYU Langone Health | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07386730 | Jun 2026 → Feb 2030 expected | — | Jennifer Mitchell | Recruiting | No outcome recorded |
| Phase 1 | NCT07347405 | May 2026 → Jan 2028 expected | obsessive-compulsive disorder | Francisco A Moreno | Recruiting | No outcome recorded |
| Phase 1 | NCT07506395 | May 2026 → May 2027 expected | post-traumatic stress disorder | University of New Mexico | Recruiting | No outcome recorded |
| Phase 1 | NCT07516405 | Apr 2026 → Mar 2028 expected | — | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1 | NCT06818994 | Apr 2026 → Jun 2027 expected | — | Gustavo Vazquez | Recruiting | No outcome recorded |
| Phase 1 | NCT07275970 | Feb → Mar 2026 overdue | post-traumatic stress disorder | Suzanne "Sue" Sisley MD | Recruiting | No outcome recorded |
| Phase 1 | NCT07053917 | Feb 2026 → Feb 2027 expected | hemiplegia, intracerebral hemorrhage, ischemic stroke | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT06988319 | Jan → Dec 2026 expected | chronic pain syndrome | Oregon Health and Science University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07079930 | Dec 2025 → Nov 2026 expected | — | Hadassah Medical Organization | Recruiting | No outcome recorded |
| Phase 1 | NCT07490353 | Nov 2025 → May 2028 expected | atypical depressive disorder, major depressive disorder | Medical University of Vienna | Recruiting | No outcome recorded |
| Phase 1 | NCT06367738 | Nov 2025 → Dec 2026 expected | — | University of California, Berkeley | Recruiting | No outcome recorded |
| Phase 1 | NCT07180108 | Aug 2025 → Jun 2028 expected | — | Johns Hopkins University | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06692192 | Aug 2025 → Dec 2027 expected | — | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 1 | NCT06919640 | Jun 2025 → Apr 2028 expected | chronic pain syndrome | Joshua Woolley, MD, PhD | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06160284 | May 2025 → Jan 2027 expected | substance-related disorder | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT06615908 | May 2025 → Oct 2026 expected | — | University of Calgary | Recruiting | No outcome recorded |
| Phase 1 | NCT06796361 | Apr 2025 → Aug 2026 overdue | — | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
| Phase 1 | NCT06835699 | Apr 2025 → Aug 2026 overdue | — | Johns Hopkins University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06884514 | Apr 2025 → May 2026 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT06899334 | Apr 2025 → Aug 2026 overdue | — | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
| Phase 1 | NCT05866471 | Jan 2025 → Nov 2027 expected | congenital vagal hyperreflexivity | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 1 | NCT05562973 | Jan → Dec 2025 | post-traumatic stress disorder | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 1 | NCT06450210 | Dec 2024 → Jul 2026 overdue | — | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT06430541 | Nov 2024 → Dec 2026 expected | breast cancer, ovarian cancer | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1 | NCT06644170 | Nov 2024 → Sep 2025 | hematopoietic and lymphoid system neoplasm, metastatic malignant neoplasm | University of Washington | Completed | No outcome recorded |
| Phase 1 | NCT06660381 | Nov 2024 → Nov 2026 expected | cannabis dependence | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT06731621 | Nov 2024 → Aug 2027 expected | autism spectrum disorder | Centre for Addiction and Mental Health | Recruiting | No outcome recorded |
| Phase 1 | NCT06442423 | Oct 2024 → Dec 2027 expected | anxiety, major depressive disorder, obsessive-compulsive disorder, post-traumatic stress disorder +1 | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT06506019 | Oct 2024 → Sep 2026 expected | bipolar depression | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 1 | NCT06299319 | Sep 2024 → Jun 2026 overdue | obsessive-compulsive disorder | Centre for Addiction and Mental Health | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06407635 | Jun 2024 → Mar 2026 overdue | post-traumatic stress disorder | Johns Hopkins University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06355414 | Apr 2024 → Jul 2026 overdue | chronic pain syndrome, depressive disorder | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT05265546 | Mar 2024 → Dec 2028 expected | perceptual disorders | University of California, Berkeley | Recruiting | No outcome recorded |
| Phase 1 | NCT05592379 | Nov 2023 → Feb 2025 | — | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1 | NCT05042466 | Sep 2023 → Aug 2025 | nervous system injury | NWTraumatherapies | Unknown | No outcome recorded |
| Phase 1 | NCT05698511 | Jul 2023 → Jan 2026 overdue | — | Robin Carhart-Harris, PhD, MA | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05370911 | Jul 2023 → Feb 2026 overdue | obsessive-compulsive disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05227612 | Jun 2023 → Sep 2025 | major depressive disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1 | NCT05467761 | Jun 2023 → Mar 2024 | — | University of Wisconsin, Madison | Withdrawn | No outcome recorded |
| Phase 1 | NCT05220046 | Apr 2023 → May 2026 overdue | biliary tract cancer, malignant pancreatic neoplasm | University of Nebraska | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05322954 | Mar 2023 → Mar 2024 | methamphetamine dependence | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 1 | NCT05557643 | Jan 2023 → Sep 2024 | depressive disorder | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT05506982 | Nov 2022 → Apr 2024 | cancer, hematopoietic and lymphoid cell neoplasm | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT06258031 | Oct 2022 → Jun 2024 | obsessive-compulsive disorder | Imperial College London | Completed | No outcome recorded |
| Phase 1 | NCT05224336 | Oct 2022 → Mar 2024 | — | University of California, San Diego | Completed | No outcome recorded |
| Phase 1 | NCT05305105 | Jul 2022 → Oct 2024 | Lyme disease, post-treatment Lyme disease syndrome | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT05478278 | Jun 2022 → Aug 2023 | — | Usona Institute | Completed | No outcome recorded |
| Phase 1 | NCT07710027 | Oct 2021 → Mar 2022 | — | Diamond Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04424225 | Aug 2021 → Sep 2023 | perceptual disorders | University of Minnesota | Terminated | No outcome recorded |
| Phase 1 | NCT04905121 | Aug 2021 → Apr 2022 | trigeminal autonomic cephalalgia | Beckley Psytech Limited | Terminated | No outcome recorded |
| Phase 1 | NCT04218539 | Aug 2021 → Nov 2023 | migraine disorder | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT04842045 | May 2021 → Nov 2022 | amnestic disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1 | NCT04161066 | Jan 2021 → Dec 2026 expected | substance-related disorder | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 1 | NCT04052568 | Aug 2019 → Jan 2022 | anorexia nervosa | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT03806985 | Mar 2019 → Jun 2023 | traumatic encephalopathy | Yale University | Terminated | No outcome recorded |
| Phase 1 | NCT03300947 | Jan 2019 → Oct 2023 | obsessive-compulsive disorder | University of Arizona | Completed | No outcome recorded |
| Phase 1 | NCT03356483 | Nov 2018 → Jul 2024 | obsessive-compulsive disorder | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03554174 | Feb 2018 → Jul 2021 overdue | major depressive disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02950467 | Jan 2018 → Dec 2019 | depressive disorder | Joshua Woolley | Completed | No outcome recorded |
| Phase 1 | NCT03341689 | Nov 2017 → Apr 2021 | migraine disorder | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03289949 | Mar 2017 → Jun 2030 expected | — | Gitte Moos Knudsen | Recruiting | No outcome recorded |
| Phase 1 | NCT02421263 | Apr 2015 → Jun 2020 | — | NYU Langone Health | Completed | No outcome recorded |
| Phase 1 | NCT02243813 | Mar 2015 → May 2024 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT02163707 | Jun 2014 → Dec 2015 | — | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1 | NCT02145091 | May 2014 → Dec 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT02033707 | Apr 2014 → Feb 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01988311 | May 2013 → Jan 2014 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT00802282 | Aug 2009 → Feb 2014 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1/217 trials | ||||||
| Phase 1/2 | NCT07079852 | Sep 2026 → Aug 2028 expected | — | Manoj Doss | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07499583 | Aug 2026 → Jan 2031 expected | substance-related disorder | Indiana University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07610135 | Jul 2026 → Jun 2028 expected | — | Johns Hopkins University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07251491 | May 2026 → Mar 2028 expected | major depressive disorder, spinal cord injury | James J. Peters Veterans Affairs Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07281352 | Jan 2026 → Nov 2027 expected | major depressive disorder | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06814522 | Jan 2025 → Jun 2027 expected | — | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06471959 | Jan → Jul 2025 | — | Empower Research Inc | Unknown | No outcome recorded |
| Phase 1/2 | NCT06898606 | Sep 2024 → Aug 2026 overdue | depressive disorder | Federal University of Latin American Integration | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04754061 | Jan 2024 → Oct 2026 expected | mixed anxiety and depressive disorder | Ottawa Hospital Research Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05351541 | Dec 2023 → Jul 2026 overdue | chronic pain syndrome | Joshua Woolley, MD, PhD | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05847686 | Jun 2023 → Apr 2024 | hematopoietic and lymphoid system neoplasm, metastatic malignant neoplasm | University of Washington | Completed | No outcome recorded |
| Phase 1/2 | NCT04982796 | Jul 2022 → Dec 2026 expected | substance-related disorder | Portland VA Research Foundation, Inc | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05301608 | Mar 2022 → Jul 2026 overdue | — | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04505189 | May 2021 → Dec 2023 | anorexia nervosa | Imperial College London | Completed | No outcome recorded |
| Phase 1/2 | NCT04280055 | Jan → Nov 2020 | cluster headache syndrome | Gitte Moos Knudsen | Terminated | No outcome recorded |
| Phase 1/2 | NCT02971605 | Jul 2017 → Aug 2018 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1/2 | NCT00302744 | Apr 2004 → Dec 2008 | anxiety | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
| Phase 2111 trials | ||||||
| Phase 2 | NCT06005662 | Apr 2027 → Jul 2028 | substance-related disorder | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 2 | NCT07566104 | Jan 2027 → Dec 2028 expected | major depressive disorder | University of California, Los Angeles | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07227909 | Nov 2026 → Jan 2029 expected | peripheral neuropathy | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06827054 | Aug 2026 → May 2027 expected | cancer, hematopoietic and lymphoid system neoplasm | Roswell Park Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07104916 | Jul 2026 → Sep 2029 expected | major depressive disorder, post-traumatic stress disorder | Anthony P King | Recruiting | No outcome recorded |
| Phase 2 | NCT07479550 | Jul 2026 → Jul 2027 expected | major depressive disorder | Stanford University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07610369 | Jul 2026 → Jul 2030 expected | Parkinson disease, depressive disorder | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT07296094 | Jun 2026 → Dec 2029 expected | alcohol-related disorders | Brigham and Women's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07582120 | Jun 2026 → Jun 2031 expected | depressive disorder | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06386003 | Jun 2026 → Jan 2027 expected | post-traumatic stress disorder | Unity Health Toronto | Recruiting | No outcome recorded |
| Show all 111 trials opens the full record — a long page | ||||||
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07570654 | Sep 2026 → Nov 2028 expected | post-traumatic stress disorder | COMPASS Pathways | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05398484 | May 2023 → Jan 2027 expected | cancer of unknown primary site | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT07226232 | Jul 2026 → Dec 2030 expected | major depressive disorder | VA Office of Research and Development | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07638553 | Jun 2026 → Jun 2030 expected | alcohol-related disorders, depressive disorder | Nîmes University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06943573 | May 2026 → Dec 2028 expected | bipolar II disorder | Lakshmi N Yatham | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07703722 | Apr 2026 → Oct 2027 expected | major depressive disorder, post-traumatic stress disorder | Khyber Medical University Peshawar | Recruiting | No outcome recorded |
| Phase 3 | NCT07063862 | Jan 2026 → Aug 2027 expected | — | Bruyère Health Research Institute. | Recruiting | No outcome recorded |
| Phase 3 | NCT06247839 | Sep 2024 → Jun 2028 expected | major depressive disorder | Sharmin Ghaznavi | Recruiting | No outcome recorded |
| Phase 3 | NCT06303739 | Apr 2024 → Apr 2026 overdue | major depressive disorder | University of North Carolina, Chapel Hill | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06308653 | Mar 2024 → Jan 2026 overdue | major depressive disorder | Usona Institute | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05711940 | Feb 2023 → Feb 2026 overdue | — | COMPASS Pathways | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05624268 | Jan 2023 → May 2025 overdue | — | COMPASS Pathways | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05163496 | Mar 2022 → Dec 2023 | COVID-19, depressive disorder, post-traumatic stress disorder | University of Washington | Completed | No outcome recorded |
| Phase not applicable12 trials | ||||||
| — | NCT06647056 | Dec 2024 → Jan 2025 | psychogenic movement disorders | Nîmes University Hospital | Completed | No outcome recorded |
| — | NCT06650800 | Nov 2024 → Mar 2025 | major depressive disorder, substance-related disorder | Nîmes University Hospital | Completed | No outcome recorded |
| — | NCT06529939 | Nov 2024 → Sep 2025 overdue | psychiatric disorder | Western University, Canada | Not yet recruiting | No outcome recorded |
| — | NCT06560658 | Oct 2024 → Oct 2025 | — | National University of Natural Medicine | Withdrawn | No outcome recorded |
| — | NCT06372197 | Aug 2024 → May 2025 | depressive disorder | Matthew Hicks | Completed | No outcome recorded |
| — | NCT06368492 | May 2024 → Dec 2025 overdue | fibromyalgia | Maastricht University | Recruiting | No outcome recorded |
| — | NCT05723276 | Feb 2024 → May 2026 overdue | conversion disorder | King's College London | Active not recruiting | No outcome recorded |
| — | NCT06235411 | Feb → Nov 2024 | alcohol dependence, depressive disorder | Nîmes University Hospital | Completed | No outcome recorded |
| — | NCT05651126 | Dec 2022 → Aug 2024 | autism spectrum disorder | King's College London | Completed | No outcome recorded |
| — | NCT05570708 | Oct 2022 → Jun 2029 expected | — | Felix Mueller | Enrolling by invitation | No outcome recorded |
| — | NCT03736980 | Oct 2013 → Dec 2018 | — | University of Zurich | Completed | No outcome recorded |
| — | NCT01943994 | Sep 2008 → May 2023 | nicotine dependence | Johns Hopkins University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 28 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07449351 Comparator | Aug 2026 → Apr 2028 expected | — | Yale University | Not yet recruiting | No outcome recorded |
| Phase 113 trials | ||||||
| Phase 1 | NCT07433452 Comparator | Sep 2026 → Sep 2028 expected | — | Gabriella Gobbi | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07693153 Comparator | Aug 2026 → Dec 2031 expected | — | Yale University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06989957 Comparator | Sep 2025 → Aug 2028 expected | post-traumatic stress disorder | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT07050368 Comparator | Jul 2025 → Jan 2026 | — | MycoMedica Life Sciences PBC | Completed | No outcome recorded |
| Phase 1 | NCT06815653 Background | Mar 2025 → Mar 2026 overdue | — | University College, London | Recruiting | No outcome recorded |
| Phase 1 | NCT06772753 Comparator | Feb 2025 → Jun 2027 expected | — | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT06643637 Comparator | Nov 2024 → Mar 2025 | — | MycoMedica Life Sciences PBC | Completed | No outcome recorded |
| Phase 1 | NCT06326606 Comparator | Mar → Jul 2024 | — | MycoMedica Life Sciences PBC | Completed | No outcome recorded |
| Phase 1 | NCT06081179 Comparator | Oct 2023 → Sep 2025 | — | University of Zurich | Completed | No outcome recorded |
| Phase 1 | NCT05523401 Comparator | Aug 2023 → Oct 2024 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT05317689 Comparator | May 2022 → Jan 2025 overdue | — | University of California, San Francisco | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04227756 Comparator | May 2020 → Sep 2022 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT02981173 Comparator | Dec 2016 → Jun 2022 | cluster headache syndrome | Yale University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06992999 Comparator | Sep 2026 → Dec 2028 expected | obsessive-compulsive disorder | Francisco A Moreno | Not yet recruiting | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT06885996 Comparator | Aug 2026 → Aug 2028 expected | post-traumatic stress disorder | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07306364 Comparator | Jun 2026 → Jun 2029 expected | chronic pain syndrome | Yale University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07169747 Comparator | Apr → Oct 2026 expected | anorexia nervosa | Region Skane | Recruiting | No outcome recorded |
| Phase 2 | NCT07072728 Comparator | Oct 2025 → Dec 2026 expected | adjustment disorder, breast cancer, cutaneous melanoma, endometrial cancer +4 | Psyence Australia Pty Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06592833 Comparator | Feb 2025 → Mar 2028 expected | major depressive disorder | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 2 | NCT06067737 Comparator | Feb 2024 → Jul 2028 expected | substance-related disorder | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 2 | NCT06341426 Comparator | Feb 2024 → Jul 2026 overdue | major depressive disorder | University Health Network, Toronto | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05452772 Comparator | Nov 2023 → Dec 2026 expected | nicotine dependence | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 2 | NCT04410913 Comparator | Feb 2021 → Feb 2023 overdue | alcohol-related disorders | Keith Heinzerling | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04141501 Comparator | Jun 2020 → Mar 2023 | alcohol-related disorders | University of Zurich | Completed | No outcome recorded |
| Phase 2 | NCT03715127 Comparator | Mar 2019 → Oct 2021 | major depressive disorder | University of Zurich | Completed | No outcome recorded |
| Phase 2 | NCT00979693 Comparator | Jan 2012 → Apr 2013 | anxiety, melanoma | Multidisciplinary Association for Psychedelic Studies | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05160220 Comparator | Jan → Jun 2021 | — | National Council of Scientific and Technical Research, Argentina | Completed | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 275 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Psilocybin | “METHODS: Single, acute oral doses of DXM (400 mg/70 kg), psilocybin (10, 20, 30 mg/70 kg), and inactive placebo were administered under double-blind and psychologically...” PMID 38152462 ↗ Dec 2023264“2.0mg powdered psilocybin derived from Psilocybe cubensis mushrooms, in capsules, provided three times weekly for four weeks” NCT07449351 ↗ “Each participant will ingest psilocybin from dried mushrooms in a chocolate formulation.” NCT07275970 ↗ “one dose of 25 mg of oral psilocybin on the first dosing day” NCT06206265 ↗ “non-synthesized plant medicine psilocybin” NCT05042466 ↗ |
| Known as | 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate | “An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO)...” NCT04905121 ↗1“Psilocybin (\[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate), 25mg PO.” NCT06072898 ↗ |
| Known as | 4-hydroxy-N,N-dimethyltryptamine | “Psilocybin (4-hydroxy-N,N-dimethyltryptamine) occurs in nature in many species of mushrooms, including the genera Psilocybe, Conocybe, Gymnopilus, Panaeolus, and Strophparia.” NCT06442423 ↗ |
| Known as | 4-phosphoroyloxy-N,N-dimethyltryptamine | “Psilocybin (4-phosphoroyloxy-N,N-dimethyltryptamine) is a hallucinogenic tryptamine that was first isolated from Psilocybe mushrooms in 1957.” NCT02163707 ↗ |
| Known as | 4-phosphoryloxy- N,N-dimethyl-tryptamine | “Early clinical studies using the psychotropic compound psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) as an adjunct in psychotherapy reported a significant improvement of...” NCT03715127 ↗2“Psilocybin (4-phosphoryloxy- N,N-dimethyl-tryptamine) is a psychedelic (hallucinogenic) compound found in certain species of mushrooms” NCT00979693 ↗ “Participants may receive varying oral psychoactive doses of psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine)” NCT06772753 ↗ |
| Known as | APEX-002-A02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06141876 ↗ |
| Known as | BPL-PSILO | “An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO)...” NCT04905121 ↗ |
| Known as | COMP360 | “Participants (N=233) with treatment-resistant depression received a single dose of 25, 10, or 1 mg of COMP360 psilocybin (a synthesized, pharmaceutical-grade, proprietary...” PMID 41362124 ↗ Dec 20253“trial of escitalopram and investigational drug, COMP360, psilocybin, in the treatment of major depressive disorder” PMID 38247730 ↗ Jan 2024 “COMP360 (Brand name of psilocybin to be used)” NCT06247839 ↗ “Psilocybin (COMP360)” NCT06258031 ↗ |
| Known as | Magic Mushrooms | “Other Names: "Magic Mushrooms"” NCT05370911 ↗ |
| Known as | MLS101 | “MLS101 is being developed as a low dose psilocybin” NCT07050368 ↗ |
| Known as | NPX-5 | “Participants in Group 1 will receive a single dose of 25 mg NPX-5 psilocybin capsules under medical supervision on Day 14.” NCT07072728 ↗ |
| Known as | PEX010 | “A single administration of PEX010 (psilocybin 25 mg, opaque capsule for oral ingestion). PEX010 contains psilocybin (25 mg) naturally extracted from Psilocybe cubensis mushroom...” NCT04718792 ↗7“High Dose (25mg) PEX010 (Oral Psilocybin), 25mg; single dose (38 participants) administered 24hrs prior to first ACT session” NCT06885996 ↗ “Psilocybin PEX010 is an investigational drug provided in capsule form, containing a 25 mg dose of synthetic psilocybin.” NCT06815653 ↗ “Group 1: Psilocybin PEX010 (25 mg) + trazodone placebo (pharmaceutical master preparation prepared according to GPP)” NCT07210112 ↗ “The first session of psilocybin PEX010 administration will use a moderately high dose of psilocybin, i.e., 25 mg.” NCT07391332 ↗ “It will be in a capsule of 25mg psilocybin (PEX010).” NCT06378229 ↗ “PEX010 is the psilocybin produced by Filament” NCT06810310 ↗ “PSILOCYBIN (PEX010) 25 mg PO single dose” NCT06731335 ↗ |
| Known as | psi | “received zero, one, or two doses of psilocybin (10 mg; psi).” PMID 41459830 ↗ Dec 2025 |
| Known as | Psilocybine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03715127 ↗ |
| Known as | TRP-8802 | “Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy” NCT06206265 ↗ |
| Known as | TRYP-0082 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05035927 ↗ |
| Action | Activate | “classic psychedelics (5-HT2A receptor agonists or partial agonists) such as psilocybin might facilitate behavior change” PMID 36332827 ↗ Nov 2022 |
| Modality | Other / unclassified | “a serotonergic psychoactive agent” NCT00957359 ↗ |
| Route | Oral | “25 mg psilocybin administered orally once during each of the two day-long psychotherapy sessions” NCT00979693 ↗ |